[PDF][PDF] 6 Chung WH, Hung SI, Hong HS et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature 2004; 428: 486. 7 Beutler E. G6PD deficiency. Blood
WE Evans - Clin Med, 2009 - rcpjournals.org
Conclusions Genotype-guided prescribing is now routine in a few cases and should
increase in coming years. It will probably be most useful for drugs with a narrow therapeutic …
increase in coming years. It will probably be most useful for drugs with a narrow therapeutic …
CYP2C19* 2 status in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis
AJ Laska, MJ Han, JA Lospinoso… - Pharmacogenomics …, 2017 - Taylor & Francis
Purpose Genetic polymorphisms have been linked to an increased predisposition to
developing certain diseases. For example, patients of Han-Chinese descent carrying the …
developing certain diseases. For example, patients of Han-Chinese descent carrying the …
Pharmacogenetics through a public health lens: from policy to practice
Opinion The field of pharmacogenetics opens up avenues for physicians to consider
customizing clinical management to optimize drug dosages with the concurrent aim of …
customizing clinical management to optimize drug dosages with the concurrent aim of …
Clinical application of pharmacogenomics
The purpose of this review is to discuss the clinical application of pharmacogenomics for
select drug therapies (eg, proton pump inhibitors [PPIs], codeine, and carbamazepine) and …
select drug therapies (eg, proton pump inhibitors [PPIs], codeine, and carbamazepine) and …
[PDF][PDF] Evidence-based medicine for pharmacogenetics
MF Rossier, M Rebsamen, S Crettol, CB Eap… - researchgate.net
Evidence-based medicine for pharmacogenetics Page 1 NR. 4 | AUGUST 2010 THEME 13
economical point of view), “pharmacogenotyping” has not yet been introduced into clinical …
economical point of view), “pharmacogenotyping” has not yet been introduced into clinical …
[HTML][HTML] Current pharmacogenetic perspective on Stevens-Johnson syndrome and toxic epidermal necrolysis
L Cheng - Frontiers in Pharmacology, 2021 - frontiersin.org
Adverse drug reactions are a public health issue that draws widespread attention, especially
for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) which have high …
for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) which have high …
Psychiatric Cases: Bipolar Disorder and Stevens–Johnson Syndrome
FJ McMahon - Genomics in the Clinic, 2024 - Elsevier
Psychiatric Cases: Bipolar Disorder and Stevens–Johnson Syndrome - ScienceDirect Skip
to main contentSkip to article Elsevier logo Journals & Books Search RegisterSign in View …
to main contentSkip to article Elsevier logo Journals & Books Search RegisterSign in View …
Drug-induced Stevens–Johnson syndrome and toxic epidermal necrolysis call for optimum patient stratification and theranostics via pharmacogenomics
C Sukasem, T Katsila, T Tempark… - Annual Review of …, 2018 - annualreviews.org
The Global Genomic Medicine Collaborative, a multinational coalition of genomic and policy
experts working to implement genomics in clinical care, considers pharmacogenomics to be …
experts working to implement genomics in clinical care, considers pharmacogenomics to be …
Clinical Utility of HLA-B*58:01 Genotyping to Prevent Allopurinol-Induced SJS/TEN
Purpose: A 28-year-old male reported to our hospital with Stevens–Johnson syndrome/toxic
epidermal necrolysis (SJS/TEN) overlap syndrome that developed as an adverse drug …
epidermal necrolysis (SJS/TEN) overlap syndrome that developed as an adverse drug …
Pharmacogenetics and pharmacogenomics I: linking diagnostic classification to therapeutic decisions
MJ Murphy, C Pincelli, DM Hoss, RG Borroni - Molecular Diagnostics in …, 2011 - Springer
Innovations in medical therapy have been associated with increasing life expectancy,
improved quality of life, and with a decreasing need for hospitalizations and surgery …
improved quality of life, and with a decreasing need for hospitalizations and surgery …